Section of Interventional Cardiology, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA.
Cardiovascular Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Interv Cardiol Clin. 2021 Oct;10(4):531-539. doi: 10.1016/j.iccl.2021.05.005.
All bioprosthetic valves, both surgical and transcatheter, have a finite lifespan before their leaflets inevitably degenerate, leading to stenosis or regurgitation. As younger, low-risk patients receive a transcatheter aortic valve, it is expected that they will most likely outlive their bioprosthetic valve. The heterogeneity of studies regarding surgical valve durability makes the interpretation of the data challenging. Leaflet thickening is seen in transcatheter heart valves but currently there is no evidence that it leads to premature valve deterioration or clinical events. Standardized definitions of structural valve deterioration should allow for comparisons between future clinical trials to assess the durability of different transcatheter heart valves.
所有生物假体瓣膜，无论是外科手术植入的还是经导管植入的，在其瓣叶不可避免地退化导致狭窄或反流之前，都有一个有限的寿命。随着年轻、低风险的患者接受经导管主动脉瓣置换术，预计他们最有可能比生物假体瓣膜活得更长。关于外科瓣膜耐久性的研究存在异质性，使得数据的解释具有挑战性。在经导管心脏瓣膜中可以看到瓣叶增厚，但目前尚无证据表明瓣叶增厚会导致瓣膜提前恶化或引发临床事件。结构性瓣膜退化的标准化定义应允许在未来的临床试验之间进行比较，以评估不同经导管心脏瓣膜的耐久性。
